JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
WILMINGTON, Del., April 14, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)?
- Did you purchase your shares between May 6, 2014 and February 23, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of PTC Therapeutics (“PTC” or the “Company”) (NASDAQ:PTCT) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the District of New Jersey on behalf of all persons or entities that purchased the common stock of PTC between May 6, 2014 and February 23, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you wish to serve as lead plaintiff, you must move the Court no later than May 2, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of PTC during the Class Period, or purchased shares prior to the Class Period and still hold PTC, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/ptc-therapeutics-inc-ptct.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
